Global Schizophrenia Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027

MarketResearch.biz delivers in-depth insights on the global schizophrenia market in its upcoming report titled, “Global Schizophrenia Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027”. The global schizophrenia market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the global schizophrenia market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report offers insightful and detailed information regarding the various key players operating in the global schizophrenia market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global schizophrenia market report has been segmented on the basis of therapeutic class, treatment, and region.

Schizophrenia is a chronic mental disorder that affects how a person thinks, feels, and acts. Individuals with schizophrenia may find it difficult to distinguish between what is real and what is imaginary, may be unresponsive at times. Also, individuals that are affected by schizophrenia may have difficulty expressing normal emotions in various social situations. The exact cause of schizophrenia is unknown, but some theories about the cause include; genetics (heredity), biology (abnormalities in brain’s chemistry or structure); and/or possible viral infections and immune disorders. The treatments for schizophrenia include: antipsychotics, and specialty care.

Increasing incidence of schizophrenia in developed economies, growing awareness among individuals about treatments for schizophrenia, and increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving growth of the global schizophrenia drugs market. In addition, relatively high number of pipeline drugs, and availability of cost effective generic schizophrenia drugs are other factors expected to boost growth of the global schizophrenia drugs market over the forecast period.

However, high cost of therapies for treatment of schizophrenia, and side effects caused by intake of generic schizophrenia drugs are major factors restraining growth of the global schizophrenia drugs market. Additionally, lack of appropriate healthcare infrastructure in emerging economies, and high cots in R&D of schizophrenia drugs are other factors expected to hamper growth of the global schizophrenia drugs market over the forecast period.

Currently, the market in North America dominates the global schizophrenia market in revenue terms owing to presence of a large patient pool, and availability of appropriate healthcare infrastructure in countries in the region. The market in Europe accounted for second-highest revenue share in the global schizophrenia market, due to high healthcare expenditure by governments of countries, and increasing awareness about mental disorders, followed by markets in Asia Pacific, Latin America, and Middle East & Africa respectively. The market in Asia Pacific is projected to have fastest growth in terms of revenue, owing to presence of a large patient pool, and availability of generic drugs for schizophrenia treatment in the region.

Market Segmentation:

Global schizophrenia market segmentation by therapeutic class:

• Second-Generation Antipsychotics
  • Risperdal (Risperidone)
  • Invega (Paliperidone)
  • Zyprexa (Olanzapine)
  • Geodon (Ziprasidone)
  • Seroquel (Quetiapine)
  • Latuda (Lurasidone)
  • Aristada (Aripiprazole Lauroxil)
  • Fanapt (Iloperidone)
  • Saphris (Asenapine)
  • Vraylar (Cariprazine)
• Third-Generation Antipsychotics
  • Abilify (Aripiprazole)
• Others
  • First-Generation Antipsychotics
  • Generics

Global schizophrenia market segmentation by treatment:

• Oral Antipsychotics
• Injectable Antipsychotics

Global schizophrenia market segmentation by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company/Otsuka Holdings Co. Ltd.
• AstraZeneca
• Dainippon Sumitomo Pharma Co., Ltd.
• Alkermes
• Eli Lilly and Company
• Vanda Pharmaceuticals Inc.
• Allergan plc
• Pfizer Inc.